Spyre Therapeutics (SYRE) AI Stock Analysis

• Market Cap: $3.85B
• Dividend Yield: N/A
• Average Volume (3M): 845.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: N/A
• EPS Growth: -123.65%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.70
• Shares Outstanding: 78,540,160
• 10 Day Avg. Volume: 882,972
• 30 Day Avg. Volume: 844,997
• PEG Ratio: 1.94
• Price to Book (P/B): 15.85
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -66.98
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 31.75
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -16.03
• 1Y Price Target: $65.22
• Price Target Upside: 33.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -2.92
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: $50.00 ▲(2.08% Upside)
• Action: Reiterated Date: 02/20/26
• Date: Action: Reiterated 02/20/26

The score is anchored by weak operating fundamentals (minimal revenue, sizable losses, and continued cash burn), partially offset by a strong, debt-free balance sheet and positive corporate developments with funded runway. Technicals add support due to a clear uptrend, while valuation is constrained by negative earnings and no dividend support.

Positive Factors

Debt-free balance sheet and growing equity

A zero-debt capital structure and a large increase in shareholders' equity materially improve financial flexibility. This durable strength supports multi-year clinical programs, reduces near-term refinancing risk, and gives management optionality to fund development or pursue partnerships without leverage.

Negative Factors

Minimal revenue and sustained operating losses

As a development-stage biotech, the company lacks commercial revenue and generates substantial operating losses, which are structural until products are approved and marketed. Persistent negative earnings constrain reinvestment ability and make long-term viability dependent on financing or successful clinical outcomes.

Spyre Therapeutics Business Overview & Revenue Model

Company Description

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind s...

Read more

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind s...

How the Company Makes Money

Spyre Therapeutics does not primarily generate revenue from product sales because its programs are in clinical development and not commercialized. Its potential or typical sources of funding and revenue for a clinical-stage biotech include: (1) ra...

Read more

Spyre Therapeutics does not primarily generate revenue from product sales because its programs are in clinical development and not commercialized. Its potential or typical sources of funding and revenue for a clinical-stage biotech include: (1) ra...

Spyre Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	886.00K	2.33M	18.74M
Gross Profit	-171.65M	0.00	886.00K	2.33M	18.74M
EBITDA	-209.56M	-207.97M	-127.60M	-82.82M	-64.07M
Net Income	-155.20M	-208.02M	-338.79M	-83.81M	-65.80M
Balance Sheet
Total Assets	777.78M	608.48M	341.86M	71.14M	109.93M
Cash, Cash Equivalents and Short-Term Investments	756.53M	603.09M	339.28M	55.71M	93.13M
Total Debt	0.00	0.00	0.00	4.63M	5.06M
Total Liabilities	62.55M	90.68M	157.84M	20.84M	25.98M
Stockholders Equity	715.24M	517.80M	184.02M	50.30M	83.94M
Cash Flow
Free Cash Flow	-169.25M	-157.41M	-99.91M	-80.18M	-54.29M
Operating Cash Flow	-169.25M	-157.41M	-99.91M	-80.14M	-53.72M
Investing Cash Flow	-143.47M	-353.29M	-108.39M	57.01M	-22.62M
Financing Cash Flow	309.02M	410.91M	361.08M	42.68M	1.39M

Spyre Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 48.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRE, the sentiment is Positive. The current price of 48.98 is above the 20-day moving average (MA) of 44.29, above the 50-day MA of 39.94, and above the 200-day MA of 26.42, indicating a bullish trend. The MACD of 2.45 indicates Negative momentum. The RSI at 63.40 is Neutral, neither overbought nor oversold. The STOCH value of 74.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRE.

Spyre Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRAX	61 Neutral	$8.64B	-21.87	-58.74%	―	364.98%	-25.33%
SYRE	59 Neutral	$3.85B	-45.32	-29.44%	―	―	-123.65%
OCS	53 Neutral	$1.51B	-8.77	-62.46%	―	―	-25.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
UPB	50 Neutral	$528.96M	-10.19	-36.48%	―	―	―
EYPT	48 Neutral	$1.09B	-5.61	-88.31%	―	-7.38%	-49.03%
SPRY	48 Neutral	$833.10M	-6.70	-100.29%	―	5459.66%	-59.70%

Spyre Therapeutics Corporate Events